Valuation: Emcure Pharmaceuticals Limited

Market Cap 34TCr 353.72Cr 314.85Cr 291.8Cr 264.42Cr 496.93Cr 505.25Cr 3.5TCr 1.38TCr 18TCr 1.33TCr 1.3TCr 56TCr P/E 2027 *
28.2x
P/E 2028 * 23x
Enterprise Value 34TCr 360.46Cr 320.84Cr 297.36Cr 269.45Cr 506.4Cr 514.88Cr 3.57TCr 1.4TCr 18TCr 1.35TCr 1.32TCr 57TCr EV / Sales 2027 *
3.22x
EV / Sales 2028 * 2.78x
Free-Float
22.18%
Yield 2027 *
0.23%
Yield 2028 * 0.27%
02/10 Emcure Pharmaceuticals Limited Receives Income-Tax Department Orders Imposing Aggregate Penalty of INR 577.396732 Million CI
23/09 Emcure Pharmaceuticals Limited Approves Final Dividend for the Financial Year Ended March 31, 2026 CI
16/09 Gilead Sciences Expands Licensing Agreements for HIV Treatment MT
06/08 Emcure Pharmaceuticals Limited, Q1 2027 Earnings Call, Aug 06, 2026
06/08 Emcure Pharmaceuticals Limited Recommends Final Dividend for the Financial Year Ended March 31, 2026 CI
06/08 Emcure Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
06/08 Emcure Pharmaceuticals Limited Announces Board and Management Changes CI
21/07 Emcure Pharmaceuticals Limited Announces Cessation of P.S. Jayakumar as Independent Director and from Board Committees, Effective July 21, 2026 CI
21/07 Emcure Pharmaceuticals Limited completed the acquisition of an additional unknown minority stake in Gennova Biopharmaceuticals Ltd. from Sanjay Singh. CI
20/07 Emcure Pharmaceuticals Limited Expands Use Of Poviztra For MASH Indication Following CDSCO Approval CI
13/07 Emcure Pharmaceuticals Limited executed a share transfer agreement to acquire an additional unknown minority stake in Gennova Biopharmaceuticals Ltd. from its shareholders. CI
13/07 Emcure Pharmaceuticals Limited executed a share transfer agreement to acquire an additional unknown minority stake in Gennova Biopharmaceuticals Ltd. from Sanjay Singh. CI
03/07 Emcure Pharmaceuticals Unit to Acquire Remaining Shares in Canada's Mantra Pharma for C$50 Million MT
1 day-2.97%
1 week-5.40%
Current month-9.08%
1 month-11.84%
3 months-0.93%
6 months+5.65%
Current year+29.47%
1 week 1,746.5
Extreme 1746.5
1,887.9
1 month 1,746.5
Extreme 1746.5
2,045
Current year 1,381
Extreme 1381
2,100.7
1 year 1,306.5
Extreme 1306.5
2,100.7
3 years 889
Extreme 889
2,100.7
5 years 889
Extreme 889
2,100.7
10 years 889
Extreme 889
2,100.7
Manager TitleAgeSince
Chief Executive Officer 75 16/04/1981
Director of Finance/CFO - 01/10/2003
Compliance Officer - 04/02/2026
Director TitleAgeSince
Director/Board Member 73 23/07/2001
Chairman 75 21/09/2026
Director/Board Member 49 28/07/2019
Change 5-day change 1-year change 3-year change Capi.($)
-2.97%-5.40%+31.10% - 353.43Cr
+4.04%+10.18%+58.88%+119.84% 1,10600Cr
+2.30%+4.33%+33.89%+69.53% 61TCr
+2.70%+4.91%+24.03%+96.83% 50TCr
+2.58%+8.31%+37.43%+63.51% 37TCr
+4.49%+4.35%+71.63%+44.30% 35TCr
+1.85%+5.45%+21.38%+49.26% 29TCr
+1.76%+6.07%+0.43%+20.98% 26TCr
+3.94%+5.93%+44.17%+56.85% 23TCr
+2.25%+5.45%+26.70%+100.49% 19TCr
Average +2.19%+1.37%+34.96%+69.07% 39.04TCr
Weighted average by Cap. +3.02%+2.29%+40.61%+80.51%

Financials

2027 *2028 *
Net sales 11TCr 111.95Cr 100Cr 92Cr 84Cr 157.27Cr 159.9Cr 1.11TCr 435.32Cr 5.55TCr 419.91Cr 411.2Cr 18TCr 12TCr 126.14Cr 112.27Cr 104.05Cr 94Cr 177.2Cr 180.17Cr 1.25TCr 490.49Cr 6.25TCr 473.13Cr 463.32Cr 20TCr
Net income 1.19TCr 13Cr 11Cr 10Cr 9.39Cr 18Cr 18Cr 124.29Cr 49Cr 622.47Cr 47Cr 46Cr 1.99TCr 1.45TCr 15Cr 14Cr 13Cr 11Cr 22Cr 22Cr 151.97Cr 60Cr 761.14Cr 58Cr 56Cr 2.43TCr
Net Debt 638.41Cr 6.74Cr 6Cr 5.56Cr 5.04Cr 9.47Cr 9.63Cr 67Cr 26Cr 334.09Cr 25Cr 25Cr 1.07TCr -327.82Cr -3.46Cr -3.08Cr -2.85Cr -2.59Cr -4.86Cr -4.94Cr -34Cr -13Cr -171.55Cr -13Cr -13Cr -547.27Cr
Projected Income Statement - Annual - Emcure Pharmaceuticals Limited
Logo Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited is an India-based pharmaceutical company, which is engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several major therapeutic areas. It offers a range of products and services under formulations, biologics and Active Pharmaceutical Ingredient (APIs). It operates across a wide scope of areas, including Gynecology, Cardiovascular, HIV Antivirals, VMN (Vitamins, Minerals & Nutrients), Pain/Analgesics, Nephrology, Oncology, Anti-Infective, Respiratory, CNS. Its brands include Orofer XT and Pause (Gynecological), Proxym (pain), Tenectase (CNS), Vylda (diabetology), Vitanova (VMN). Its API products include S-Amlodipine, Ferric Carboxymaltose, Ferrous Ascorbate and Eribulin. Its biologics business offers various products, including Elaxim (Tenecteplase), Vintor (Erythropoietin), TENECTASE (Tenecteplase). It has developed two platforms: Mammalian and Microbial.
Employees
6,914
Date Price Change Volume
19/26/19 ₹1,766.60 -2.97% 1,08,214
16/26/16 ₹1,820.60 -0.84% 39,565
15/26/15 ₹1,836.00 -1.62% 66,977
14/26/14 ₹1,866.20 -0.13% 1,57,573
13/26/13 ₹1,868.60 +0.06% 55,653
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Emcure Pharmaceuticals Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1,766.60INR
Average target price
2,229.38INR
Spread / Average Target
+26.20%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Emcure Pharmaceuticals Limited
  1. Stock Market
  2. Stocks
  3. EMCURE Stock